Rebif ®
interferon beta-1a
For over 25 years Rebif® has been by the side of people with MS. Today, Rebif® is supported by over 1.5 million patient-years of therapy* and is approved in more than 90 countries worldwide.5,6 With proven efficacy and a well-established safety profile, 1-4,7 Rebif® continues to be a trusted and effective treatment for relapsing MS. Experience matters.
INDICATIONS
Rebif® is indicated for the treatment of
• Patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.
• Patients with relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years.
FOOTNOTES AND REFERENCES
*MAVENCLAD is indicated for the treatment of adult patients with highly active RMS as defined by clinical or imaging features
**There are currently no head-to-head trials. From publicly available information, accurate at date of creation – September 2018
†Disease control refers to 75.6% of patients who remained relapse-free without further treatment in Years 3 and 43
††See Rebif prescribing information for more details.
- MAVENCLAD® SmPC, 2017.
- Giovannoni G et al. N Engl J Med 2010; 362:416–426.
- Giovannoni G et al. EAN 2017; [P0542].
- Giovannoni G et al. Mult Scler 2017; doi: 10.1177/1352458517727603.
- Rebif® EU Summary of Product Characteristics, December 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf [Accessed 25 April 2018].
- De Stefano N et al. J Neurol Sci 2012; 312:97–101.
- Kappos L et al. J Neurol Neurosurg Psychiatry 2015; 86:1202–1207
DMD – disease modifying drug
MRI – magnetic resonance imaging
MS – multiple sclerosis
RMS – relapsing multiple sclerosis